Introduction

Renal cell carcinoma (RCC) is the third most common type of urological tumor after prostate and bladder tumors. Starting from the evidences that RCC expresses antigen recognized by immune system, particularly by cytotoxic T- lymphocytes (CTLs) which can induce the development of a tumor – rejection-type immune response, the new RCC line is capable of activating the immune system in an antigen specific manner DC-mediated.

Technical features

Renal cell carcinoma (RCC) is the third most common type of urological tumor. The treatment options for RCC are surgery, radiation therapy, chemotherapy, immunotherapy, or combinations of these. Chemotherapy has not yielded satisfactory results showing that RCC is highly resistant to a range of chemotherapeutic agents administered either in combination or not in combination. Starting from the evidences that RCC expresses antigen recognized by immune system, particularly by cytotoxic T- lymphocytes which can enable the development of a tumor- rejection-type immune response, the new RCC line is capable of activating the immune system in an antigen specific manner DC-mediated. This renal immunogenic cell line can be used to undertake a co-development of DC-based vaccine, to produce the antigenic format Elthem-derived (lysate) for DC-loading under GMP conditions and to produce the GMP vaccine for the treatment of RCC patients.

Possible Applications

• Vaccine development;
• Identification of new biomarkers;
• Setting of new commercial kits for the dosing of diagnostic markers / prognostic of renal tumor.

Advantages

• New adjuvant treatment;
• High immunogenicity.